BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Bioinformatics Software | QIAGEN Digital Insights - ECPv6.15.17.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bioinformatics Software | QIAGEN Digital Insights
X-ORIGINAL-URL:https://staging.digitalinsights.supremeclients.com
X-WR-CALDESC:Events for Bioinformatics Software | QIAGEN Digital Insights
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Halifax
BEGIN:DAYLIGHT
TZOFFSETFROM:-0400
TZOFFSETTO:-0300
TZNAME:ADT
DTSTART:20220313T060000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0300
TZOFFSETTO:-0400
TZNAME:AST
DTSTART:20221106T050000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0400
TZOFFSETTO:-0300
TZNAME:ADT
DTSTART:20230312T060000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0300
TZOFFSETTO:-0400
TZNAME:AST
DTSTART:20231105T050000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0400
TZOFFSETTO:-0300
TZNAME:ADT
DTSTART:20240310T060000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0300
TZOFFSETTO:-0400
TZNAME:AST
DTSTART:20241103T050000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231214T130000
DTEND;TZID=America/New_York:20231214T150000
DTSTAMP:20260403T183354
CREATED:20231108T123505Z
LAST-MODIFIED:20241024T182952Z
UID:10000705-1702558800-1702566000@staging.digitalinsights.supremeclients.com
SUMMARY:RNA-seq data analysis and interpretation with sankey plot update
DESCRIPTION:During this 120-minute training\, we’ll teach you how to easily analyze and interpret RNA-seq data using QIAGEN CLC Genomics Workbench and QIAGEN Ingenuity Pathway Analysis (IPA) software.  For RNA-seq data\, you will learn how to: • Import FASTQ files\, cell-matrix files and metadata and how to download references • Map reads to a reference genome and generate gene and transcript counts and QC reports displaying % mapped reads\, knee plots\, etc. • Generate visualizations of results\, such as heatmaps\, differential expression tables\, PCA/PCOA plots\, Venn diagrams\, sankey plot and others • Easily customize RNA-seq workflows • Export publication-quality graphics\, tables and reports • Send differential expression tables to QIAGEN Ingenuity Pathway Analysis directly from QIAGEN CLC Genomics Workbench to analyze and interpret relevant pathways  Here you can explore the types of analyses and visualizations you'll learn to generate (slides from previous training): https://qiagen.showpad.com/share/qiZLmCUS32GZNM1B4llMf 
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/rna-seq-data-analysis-and-interpretation-with-sankey-plot-update/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Training
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1140_5_QDI_CLC_V22_16x9_Large-1200px_58739.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231213T110000
DTEND;TZID=America/New_York:20231213T120000
DTSTAMP:20260403T183354
CREATED:20231201T164654Z
LAST-MODIFIED:20241024T182954Z
UID:10000710-1702465200-1702468800@staging.digitalinsights.supremeclients.com
SUMMARY:One tool to help biopharma accelerate cancer drug discovery and repurposing: A translational research use-case and discussion
DESCRIPTION:The development of new cancer drugs is challenging\, costly\, and time-consuming. As translational research on cancer diagnostics and genomic profiling rapidly evolves\, the ability to confidently and efficiently identify specific oncogenes and tumor suppressors involved in oncogenesis is becoming increasingly difficult. \nThis brief half-hour webinar is intended for biopharmaceutical and biotechnology professionals who need more efficient ways of discovering\, developing\, and repurposing drugs for oncology applications. During the session\, attendees will explore a demonstration and a use-case presented by Dr. Kyle Nilson\, providing insights into the Human Somatic Mutation Database (HSMD)—a new somatic database developed by QIAGEN that contains extensive genomic content relevant to solid tumors and hematological malignancies. \nHSMD is an exceptional resource for biopharmaceutical and biotechnology companies\, facilitating the confident evaluation of cancer-related genetic variations by granting access to real-world data. Powered by QIAGEN’s extensive artificial intelligence (AI)-enabled Knowledge Base\, robust curation team composed of over 100 expert curators (MD and PhD level)\, and data from QIAGEN’s professional variant interpretation service (previously N-of-One)\, HSMD encompasses a vast repository of over 4.7 million meticulously curated genetic alteration findings and variant data over 500\,000 somatic patient cases. Attendees will explore how HSMD enables biopharmaceutical and biotechnology companies to gain deeper insights into the molecular cancer profiles\, identify therapeutic options\, and develop strategies for finding new therapies for a particular cancer type or even for a particular patient. \nAttendees will: \n\nLearn what content sources power HSMD\nUnderstand how to use and apply HSMD for multiple applications\, including translational research and pharmaceutical development\nExamine a use case of how to use HSMD to accelerate research\, development and repurposing in cancer drug development programs\nReceive a complimentary 5-day trial of HSMD
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/one-tool-to-help-biopharma-accelerate-cancer-drug-discovery-and-repurposing-a-translational-research-use-case-and-discussion/
CATEGORIES:Clinical,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1144_5_QDI_QCI_HSMD_GI646221430_16x9_59476_Large-1200px-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231213T100000
DTEND;TZID=America/New_York:20231213T110000
DTSTAMP:20260403T183354
CREATED:20231108T123149Z
LAST-MODIFIED:20241024T182953Z
UID:10000706-1702461600-1702465200@staging.digitalinsights.supremeclients.com
SUMMARY:How to perform DNA-seq and resequencing data analyses using QIAGEN CLC Genomics Workbench
DESCRIPTION:In this webinar\, we’ll introduce algorithms required to perform data analysis for resequencing next-generation sequencing data. Together\, we’ll explore:  • Read mapper • Variant callers • Annotations and filters • Genome Browser  Bring any questions you may have\, and we will answer them during the webinar. 
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/how-to-perform-dna-seq-data-analysis-with-clc-genomics-workbench-resequencing/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1109_4_QDI_CLC_Challenger_Or55819-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231212T130000
DTEND;TZID=America/New_York:20231212T140000
DTSTAMP:20260403T183354
CREATED:20231108T122647Z
LAST-MODIFIED:20241024T182950Z
UID:10000704-1702386000-1702389600@staging.digitalinsights.supremeclients.com
SUMMARY:Target exploration and cell line selection for drug discovery
DESCRIPTION:Cancer cell line models have been a cornerstone of cancer research for decades. Cancer cell lines profiling can be a powerful tool for the identification of genes’ alterations or pathways cancer-related and for the discovery of putative drug targets. This webinar will focus using Qiagen OmicSoft Lands and Ingenuity Pathway Analysis as guides for the selection of cell lines and translation of insights gained from cell lines for drug target discovery. \nThis 90-minute event will show how our platform enables scientists:\n• Select appropriate cancer cell lines for a variety of applications such as drug discovery\, precision disease modeling\, understanding gene function in cancer\, immune-oncology research.\n• Examine various ‘omics data for genes of interest for expression\, mutation\, hotspots\, and gene dependency data.\n• Generate networks for hypotheses and test the in-silico to improve translation of insights derived from cell line models to the drug target identification.\n• Integrated analyses of public 'omics data and drug response phenotypes using cell line model systems by exploring data from the Library of Integrated Network-Based Cellular Signatures (LINCS).\n• How to prioritize drug targets and profile phenotypic/downstream effects of drug action by overlaying public data on user generated networks. \nOur system uses millions of curated literature findings in the QIAGEN/ IPA knowledge base and the OmicSoft digital warehouse. The presentation is intended for both those familiar with Ingenuity Pathway and newcomers interested in learning more.
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/target-exploration-and-cell-line-selection-for-drug-discovery-2/
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1063_9_OmicSoft-Single-Cell-Lands_028687_16x9.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231207T130000
DTEND;TZID=America/New_York:20231207T140000
DTSTAMP:20260403T183354
CREATED:20231108T121640Z
LAST-MODIFIED:20241024T182950Z
UID:10000703-1701954000-1701957600@staging.digitalinsights.supremeclients.com
SUMMARY:Mining curated knowledge graphs and validating with experimental datasets to accelerate your drug target discovery
DESCRIPTION:In an era of near-limitless public experimental data but little standardization\, meaningful insights are lost to noise. Large collections of quality experimental data are essential for big-picture discoveries that stand up to scrutiny.  In this webinar\, you will learn how to feed your drug discovery programs by integrating connections mined from QIAGEN Biomedical Knowledge Base with deeply-curated disease datasets from QIAGEN OmicSoft Lands.  Combining unified 'omics datasets with contextual relationship evidence from our knowledge graph\, we will address complex questions such as: • Which genes aren't expressed in normal tissue\, yet are expressed in diseases of interest\, based on experimental evidence? • Which of these proteins are cell surface proteins\, with evidence for extracellular localization? • How are these proteins related directly or indirectly to disease pathways\, and can these be connected to known drug targets? • Can we identify correlated biomarkers\, mutation targets\, clinical factors or other means of cohort selection?
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/mine-curated-knowledge-graphs-and-validate-with-experimental-datasets-for-drug-target-discovery-2-2/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1052_1_QDI_OmicSoft_16x9.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231207T110000
DTEND;TZID=America/New_York:20231207T120000
DTSTAMP:20260403T183354
CREATED:20231115T130508Z
LAST-MODIFIED:20241024T182953Z
UID:10000708-1701946800-1701950400@staging.digitalinsights.supremeclients.com
SUMMARY:Translating COSMIC's gold standard data into actionable insights
DESCRIPTION:As the vast landscape of genetic oncology continues to expand\, the ability to understand and utilize the full potential of this rich data becomes increasingly challenging. As a result\, researchers\, scientists\, and clinicians need an accessible\, streamlined and standardized way of keeping track of this potentially crucial\, ever-growing body of actionable knowledge. Over the course of 20 years\, COSMIC\, the Catalogue Of Somatic Mutations In Cancer\, has expertly curated the world’s largest\, most comprehensive database for somatic mutation information relating to human cancer. Today\, COSMIC is used worldwide by revered research and clinical institutes\, biotech and pharmaceutical companies\, and more.\n\nIn this webinar\, Leonie Hodges\, Scientific Communications Officer for COSMIC\, will delve into the wide range of datasets that COSMIC offers\, detailing the content\, how to obtain actionable insights from the genomic data\, and how to potentially use this data for real-world applications. Following the talk\, there will be a live Q&A with Jennifer Wilding\, Scientist Curator at COSMIC and Alex Holmes\, Senior Database Curator at COSMIC.\n\nBy attending this webinar\, you will learn how to:\n\nExplore the wide range of datasets that COSMIC offers\, including the Cancer Mutation Census and Mutational Signatures;\nGain insights from COSMIC’s gold standard genomic data by taking either a disease or gene centric view of your research;\nIdentify potential applications of COSMIC data and how it enables users from a plethora of disciplines to experiment and innovate with confidence.
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/translating-cosmics-gold-standard-data-into-actionable-insights/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Clinical,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1229_4_QDI_QCI_COSMIC_Actionabilityv5.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20231206T140000
DTEND;TZID=Europe/Paris:20231206T150000
DTSTAMP:20260403T183354
CREATED:20231108T121513Z
LAST-MODIFIED:20241024T182949Z
UID:10000702-1701871200-1701874800@staging.digitalinsights.supremeclients.com
SUMMARY:Mining curated knowledge graphs and validating with experimental datasets to accelerate your drug target discovery
DESCRIPTION:In an era of near-limitless public experimental data but little standardization\, meaningful insights are lost to noise. Large collections of quality experimental data are essential for big-picture discoveries that stand up to scrutiny.  In this webinar\, you will learn how to feed your drug discovery programs by integrating connections mined from QIAGEN Biomedical Knowledge Base with deeply-curated disease datasets from QIAGEN OmicSoft Lands.  Combining unified 'omics datasets with contextual relationship evidence from our knowledge graph\, we will address complex questions such as: • Which genes aren't expressed in normal tissue\, yet are expressed in diseases of interest\, based on experimental evidence? • Which of these proteins are cell surface proteins\, with evidence for extracellular localization? • How are these proteins related directly or indirectly to disease pathways\, and can these be connected to known drug targets? • Can we identify correlated biomarkers\, mutation targets\, clinical factors or other means of cohort selection?
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/mine-curated-knowledge-graphs-and-validate-with-experimental-datasets-for-drug-target-discovery-3/
LOCATION:Virtual - EMEA - CET
CATEGORIES:Discovery,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1052_1_QDI_OmicSoft_16x9.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231205T130000
DTEND;TZID=America/New_York:20231205T150000
DTSTAMP:20260403T183354
CREATED:20231106T171550Z
LAST-MODIFIED:20241024T182949Z
UID:10000701-1701781200-1701788400@staging.digitalinsights.supremeclients.com
SUMMARY:New user training: Large dataset analysis and knowledge base queries using QIAGEN Ingenuity Pathway Analysis (IPA)
DESCRIPTION:\,\nIn this training\, you’ll learn how to:\n• Upload your dataset (RNA-seq\, scRNA-seq\, proteomics\, metabolomics and more) and perform interactive core/pathway analysis in IPA\n• Understand the different result types produced (pathways\, key regulators\, impact on biological functions/diseases and more)\n• Compare different experimental conditions (treatments\, time points\, single-cell clusters\, disease types and more) and identify similarities and contrasts\n• Generate a network even without a dataset or experimental design for hypothesis generation \nFor those with IPA license\,\nTo install IPA before or after this training\, please use below installer.\nhttps://qiagen.showpad.com/share/CBv30blCPKFDUYHRWtAvI
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/new-user-training-large-dataset-analysis-and-knowledge-base-queries-using-qiagen-ingenuity-pathway-analysis-ipa-6/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Training
ATTACH;FMTTYPE=image/png:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/guy-with-new-IPA-picture.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231205T110000
DTEND;TZID=America/New_York:20231205T120000
DTSTAMP:20260403T183354
CREATED:20231120T172709Z
LAST-MODIFIED:20241024T182953Z
UID:10000709-1701774000-1701777600@staging.digitalinsights.supremeclients.com
SUMMARY:Comprehensive Molecular Tumor Analysis (CMTA) integrating RNAseq and tumor immune microenvironment (TME) for targeted therapy
DESCRIPTION:Precision oncology approaches have made great strides harnessing individual tumor mutation profiles to guide targeted therapy choices. However\, deeper molecular insights are needed to improve personalized treatment decisions that are tailored to specific molecular characteristics of a tumor. Integrating gene expression analysis in personalized oncology provides an additional level of insight that cannot be provided by genomic data alone. These analyses include evaluating expressed mutations and drug targets\, novel gene fusions\, clinically relevant signatures\, and the tumor immune microenvironment (TME). \nComprehensive Molecular Tumor Analysis (CMTA) is a NGS-based innovative tumor diagnostic test developed by Alacris Theranostics. The test integrates whole exome and transcriptomic sequencing (WES and RNAseq) and is deployed as an end-to-end accredited diagnostic platform from tumor sample uptake (FFPE or frozen) to personalized clinical interpretation report. Designed to serve all cancer patients\, CMTA is a tumor-agnostic test that displays a unique molecular view into each individual sample\, which is particularly well-suited to refractory cancers with complex patterns or tumors of unknown origin. \nIn this webinar\, Alacris Theranostics will discuss the benefits of comprehensive tumor profiling in clinical settings and present the strategy implemented in their bioinformatics pipeline to identify cancer-relevant somatic events. In addition\, the diagnostic company will share how they use QIAGEN Clinical Insight (QCI) Interpret to annotate variants and identify potential therapeutic entry-points.
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/comprehensive-molecular-tumor-analysis-cmta-integrating-rnaseq-and-tumor-immune-microenvironment-tme-for-targeted-therapy/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Clinical,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1305_6_QDI_QCI_Gi1388387853-3.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231129T100000
DTEND;TZID=America/New_York:20231129T110000
DTSTAMP:20260403T183354
CREATED:20231106T170915Z
LAST-MODIFIED:20241024T182948Z
UID:10000700-1701252000-1701255600@staging.digitalinsights.supremeclients.com
SUMMARY:QIAGEN CLC Genomics Workbench for your miRNA data analyses
DESCRIPTION:Join us for our webinar\, where we'll focus on miRNA data analysis using QIAGEN CLC Genomics Workbench and Biomedical Genomics Analysis plugin. Together\, we'll explore how you can: • Import reads and metadata • Download miRBase database • Quantify miRNA expression • Perform differential expression analysis • Visualize your results • Create and use a custom database  Bring any questions you may have\, and we will answer them during the webinar. 
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/mirna-data-analysis-with-qiagen-clc-genomics-workbench/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1140_4_QDI_CLC_V22_16x9_Large-1200px_58733.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231116T130000
DTEND;TZID=America/New_York:20231116T143000
DTSTAMP:20260403T183354
CREATED:20231012T165109Z
LAST-MODIFIED:20241024T182944Z
UID:10000694-1700139600-1700145000@staging.digitalinsights.supremeclients.com
SUMMARY:Making discoveries from public data (GEO\, SRA and more) using QIAGEN Ingenuity Pathway Analysis
DESCRIPTION:You requested it\, and we’re here to deliver. We’re excited to offer you comprehensive training on how to effectively use sample-level public data and metadata from sources like GEO\, SRA\, TCGA\, GTEx\, Blueprint\, CCLE and other sources through QIAGEN Ingenuity Pathway Analysis (IPA) and the IPA Analysis Match Explorer feature. Your trainer will walk you through use cases in related to biomarker discovery\, drug target investigation\, studying survival in custom patient cohorts\, multi-gene correlation and more. Note: The word “condition” below refers to different diseases\, disease subtypes\, treatments\, cell types\, cell lines and more.  \nIn this training\, we’ll cover topics such as: • How is a gene of interest expressed across different conditions? • Is there a correlation in expression for two genes or biomarkers of user interest for a given condition? • For a given condition of interest\, can we derive a list of genes (for example\, genes specific to a disease\, treatment or cell type)? • Can we generate custom cohorts of patients (for example\, TP53 wt vs mutant or PDCD1 high vs low expression) and then generate survival curves representing those cohorts? Can we generate p-value to see if there is a significant difference? • Recent update: Can we detect the expression of a gene in different cell types from single-cell data? 
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/making-discoveries-from-public-data-geo-sra-and-more-using-qiagen-ingenuity-pathway-analysis/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1052_1_QDI_OmicSoft_16x9.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Halifax:20231116T130000
DTEND;TZID=America/Halifax:20231116T140000
DTSTAMP:20260403T183354
CREATED:20231026T115707Z
LAST-MODIFIED:20241024T182947Z
UID:10000697-1700139600-1700143200@staging.digitalinsights.supremeclients.com
SUMMARY:How clinical labs can confidently assess cancer-associated variants with real-world data and expert-curated genomic evidence
DESCRIPTION:Across various stages of the clinical oncology workflow\, from panel design to genomic testing and molecular tumor boards\, the identification and validation of actionable genomic alterations is critical. The advent of next-generation sequencing (NGS) has led to an exponential increase in the number of variants detected in tumor testing\, posing a challenge for clinical cancer genetics professionals seeking to confidently discern clinically relevant mutations that can guide patient care decisions.\n\nJoin Dr. Umadevi Thirumurthi\, Associate Director of Global Product Management for Oncology at QIAGEN Digital Insights as she discusses how the Human Somatic Mutation Database (HSMD)\, an expert-curated somatic variant database\, can enhance your clinical NGS workflow.\n\nAttendees will learn how HSMD:\n\nCan be used to design targeted panels\, streamline somatic variant analysis\, and support molecular tumor board decisions;\nProvides access to data from over 419\,00 real-world oncology cases and human-certified expert curation\nEnables users to effortlessly explore mutational characteristics across genes\, synthesize critical information from drug labels and professional guidelines\, investigate ongoing clinical trials\, and access comprehensive annotations for each observed variant
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/how-clinical-labs-can-confidently-assess-cancer-associated-variants-with-real-world-data-and-expert-curated-genomic-evidence/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Clinical,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1144_4_QDI_QCI_HSMD_GI1227547264_Full-resolution_59165-scaled-1.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231115T130000
DTEND;TZID=America/New_York:20231115T143000
DTSTAMP:20260403T183354
CREATED:20231109T061008Z
LAST-MODIFIED:20241024T182953Z
UID:10000707-1700053200-1700058600@staging.digitalinsights.supremeclients.com
SUMMARY:Easily process your FASTQ files
DESCRIPTION:Do you ever get stuck processing raw FASTQ data or cell matrix data from your RNA-seq\, scRNA-seq or other NGS assays using? Are you interested in creating a differential expression table that’s compatible with the QIAGEN Ingenuity Pathway Analysis (IPA) software you use? In this training\, you’ll learn how to use QIAGEN CLC Genomics Workbench to easily process your FASTQ files and generate differential expression tables without using command line tools. We’ll also explore how you can generate other desired outputs\, such as volcano plots\, heatmaps\, PCA/PCOA plots and more.  \nYou can delve into more information about QIAGEN CLC Genomics Workbench here:\nhttps://digitalinsights.qiagen.com/products-overview/discovery-insights-portfolio/analysis-and-visualization/qiagen-clc-genomics-workbench/ 
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/find-out-how-ipa-users-can-process-their-fastq-files/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1040_9_QDI_ICLC_GWBv21_Gi1223402761_16x9_Large-1200px_53601.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231114T130000
DTEND;TZID=America/New_York:20231114T143000
DTSTAMP:20260403T183354
CREATED:20231012T164239Z
LAST-MODIFIED:20241024T182944Z
UID:10000693-1699966800-1699972200@staging.digitalinsights.supremeclients.com
SUMMARY:IPA deeper dive: miRNA investigation using QIAGEN Ingenuity Pathway Analysis (IPA)
DESCRIPTION:In this 90-minute training session\, you will learn how to identify target mRNAs for your miRNAs of interest and associate them with pathways\, diseases\, biological functions\, tissues and cell types.  We’ll cover topics such as: - How to analyze miRNA-seq datasets alone\, or both miRNA and corresponding mRNA datasets together - How to use QIAGEN IPA without a dataset\, using miRNA IDs - Introduction to databases and curated content specific to miRNA - How to effectively apply various filters and functionalities to identify biomarkers\, key targets and novel biological mechanisms  
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/ipa-deeper-dive-mirna-investigation-using-qiagen-ingenuity-pathway-analysis-ipa-3/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Training
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_9785_QDI_IPA_GI545875183_16x9_54188_Large-1200px.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231114
DTEND;VALUE=DATE:20231119
DTSTAMP:20260403T183354
CREATED:20231030T164514Z
LAST-MODIFIED:20241024T182948Z
UID:10000699-1699920000-1700351999@staging.digitalinsights.supremeclients.com
SUMMARY:AMP 2023
DESCRIPTION:AMP is the leading organization in the field of molecular diagnostics\, and our annual meeting is widely considered the “premier gathering” of molecular professionals. As always\, we will explore how cutting-edge technology and developments in molecular testing continue to have a major and direct impact on patient care. The AMP 2023 Program Committee is planning an impressive program to spark dialogue and engagement amongst attendees and exhibitors from around the world\, and we look forward to welcoming you to discuss the latest in molecular diagnostics and network with friends and colleagues.
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/amp-2023/
LOCATION:Salt Lake City\, Salt Lake City\, UT\, United States
CATEGORIES:Clinical,Event
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_9993_GEN_gi1134578085.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231109T130000
DTEND;TZID=America/New_York:20231109T143000
DTSTAMP:20260403T183354
CREATED:20231012T163428Z
LAST-MODIFIED:20241024T182943Z
UID:10000692-1699534800-1699540200@staging.digitalinsights.supremeclients.com
SUMMARY:Isolate typing\, strain identification and antimicrobial resistance analyses using QIAGEN CLC Genomics Workbench
DESCRIPTION:QIAGEN CLC Genomics Workbench provides tools and workflows for a broad range of bioinformatics applications\, including microbiome analysis\, isolate characterization through SNP and K-mer trees using NGS data\, and antimicrobial resistance characterization. CLC Genomics Workbench is widely used for analyses of bacterial\, viral and eukaryotic (fungal) genomes and metagenomes.  We’ll cover these topics in the training:  I. Overview of different tools within MGM application and research areas supported II. Focused review of isolate typing and characterization a. Importing data b. Utilization of metadata c. Downloading and managing references i. Database of Isolates/ Resistances/ MLST d. Walk through of Type a Known Species workflow i. Review details for each Isolate e. Creating SNP profiles to specific reference f. Generate a SNP tree for isolate comparison g. Export tabular and high-quality graphical outputs in wide range of file formats
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/isolate-typing-strain-identification-and-antimicrobial-resistance-analyses-using-qiagen-clc-genomics-workbench/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Training
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1108_8_QDI_CLC_Challenger_Or54963_16x9_56810_Large-1200px-2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20231109T100000
DTEND;TZID=UTC:20231109T120000
DTSTAMP:20260403T183354
CREATED:20230912T165909Z
LAST-MODIFIED:20241024T182939Z
UID:10000686-1699524000-1699531200@staging.digitalinsights.supremeclients.com
SUMMARY:Part 2: AI-Powered Hereditary Disease Diagnostics: Closing the Gap in Clinical Exome Completeness
DESCRIPTION:Clinical exome sequencing (CES) is increasingly being adopted by small and mid-sized laboratories to diagnose genetic diseases\, aid treatment decisions\, and provide prognostic information. However\, the exponential increase in genetic data generated from exome and genome panels poses significant workflow challenges. The ability to prioritize potentially pathogenic variants from large datasets and identify the few candidate variants becomes more difficult. This issue is further amplified in cases where labs must use deep phenotyping of patients and compare that to reference genotype-phenotype knowledge associated with each candidate variant. To overcome these challenges\, labs are beginning to implement Artificial Intelligence (AI) in their variant analysis\, interpretation and reporting workflows. \nJoin us for our 2023 Clinical Hereditary Disease Diagnostics Summit\, a free-to-attend\, two-part event exploring the opportunities and limitations of AI in hereditary disease diagnostics. Designed to help clinical diagnostic labs learn how to safely apply AI to exome and genome sequencing workflows\, the content-rich event will feature invited lectures from lab directors and clinical geneticists\, thought-provoking discussions on the future of hereditary disease diagnostics\, as well as educational presentations on the latest databases and AI-powered software for germline secondary and tertiary analysis. \nPart II: Roundtable discussion with genomics experts – November 9\, 2023 \nA panel discussion featuring experts in the field of clinical genomics that will explore the challenges and opportunities in the future of inherited disease diagnostic testing. \nFor the list of speakers and session information\, visit our event page here.
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/part-2-ai-powered-hereditary-disease-diagnostics-closing-the-gap-in-clinical-exome-completeness/
LOCATION:Virtual Global Event (Times shown in EST)
CATEGORIES:Clinical,Training
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1325_0_QDI_QCI_HGMD_blog_Gi1346512014.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231107T130000
DTEND;TZID=America/New_York:20231107T150000
DTSTAMP:20260403T183354
CREATED:20231012T162359Z
LAST-MODIFIED:20241024T182943Z
UID:10000691-1699362000-1699369200@staging.digitalinsights.supremeclients.com
SUMMARY:New user training: Large dataset analysis and knowledge base queries using QIAGEN Ingenuity Pathway Analysis (IPA)
DESCRIPTION:Join us for a 120-minute training session for new users of QIAGEN IPA. \nIn this training\, you’ll learn how to:\n• Upload your dataset (RNA-seq\, scRNA-seq\, proteomics\, metabolomics and more) and perform interactive core/pathway analysis in IPA\n• Understand the different result types produced (pathways\, key regulators\, impact on biological functions/diseases and more)\n• Compare different experimental conditions (treatments\, time points\, single-cell clusters\, disease types and more) and identify similarities and contrasts\n• Generate a network even without a dataset or experimental design for hypothesis generation \nFor those with IPA license\,\nTo install IPA before or after this training\, please use below installer.\nhttps://qiagen.showpad.com/share/CBv30blCPKFDUYHRWtAvI
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/new-user-training-large-dataset-analysis-and-knowledge-base-queries-using-qiagen-ingenuity-pathway-analysis-ipa-5/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Training
ATTACH;FMTTYPE=image/png:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/guy-with-new-IPA-picture.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Halifax:20231107T130000
DTEND;TZID=America/Halifax:20231107T140000
DTSTAMP:20260403T183354
CREATED:20231026T115258Z
LAST-MODIFIED:20241024T182945Z
UID:10000696-1699362000-1699365600@staging.digitalinsights.supremeclients.com
SUMMARY:How to scale-up comprehensive genomic profiling and deliver confident variant interpretations with QCI Interpret for Oncology
DESCRIPTION:As gene panels increase in size\, comprehensive genomic profiling and variant interpretation becomes more complex and time-consuming\, which places tremendous burden on labs needing to scale and grow case volume. QIAGEN Clinical Insights (QCI) Interpret for Oncology is a clinical decision support platform powered by augmented molecular intelligence that enables rapid\, evidence-powered comprehensive genomic profiling at scale. QCI Interpret for Oncology is supported by the world’s most comprehensive\, manually curated knowledge base and dynamically computes variant classifications according to AMP/ASCO/CAP and ACMG/AMP guidelines with transparency. Users also get access to over 500\,000 pre-formulated\, oncologist-reviewed variant interpretation summaries and can build customizable\, oncologist-ready reports with the latest diagnostic and prognostic information\, as well as biomarker-directed therapeutic information and clinical trial recommendations. With its latest release\, QCI Interpret for Oncology adds several new capabilities that further enhances the platform’s scalability and flexibility\, and enables users to significantly reduce variant research and review time. \nIn this webinar\, attendees will learn how QCI Interpret for Oncology enables you to: \n\nNavigate from VCF to final report with speed\, precision\, and confidence;\nEasily issue report addendums without the need for re-running a VCF;\nStreamline structural variant filtering based on user set thresholds and hence reduce the time and effort needed to eliminate noise and identify truly relevant variants for reporting;\nUtilize built-in AI capabilities to identify all the literature\, case reports\, drug therapies\, and clinical studies relevant to a patient’s tumor type with just one-click.
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/how-to-scale-up-comprehensive-genomic-profiling-and-deliver-confident-variant-interpretations-with-qci-interpret-for-oncology/
LOCATION:Virtual Global Event (Times shown in EST)
CATEGORIES:Clinical,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1074_1_QCI_PrecisionOncology_7264-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Halifax:20231102T130000
DTEND;TZID=America/Halifax:20231102T140000
DTSTAMP:20260403T183354
CREATED:20231026T114748Z
LAST-MODIFIED:20241024T182945Z
UID:10000695-1698930000-1698933600@staging.digitalinsights.supremeclients.com
SUMMARY:The epididymis: Balancing the burden and responsibility of fertility
DESCRIPTION:The responsibility of fertility is disproportionately placed on women\, who bear most of the health\, emotional and financial burdens. Infertility is rapidly rising\, with one in six Australian couples seeking assisted reproductive technologies to help them start a family\, and over 50% of cases involving a male factor. Despite these contributions\, we still don’t fully understand the mechanisms that create competent sperm for fertilization\, which occurs during their transit from the epididymis\, a highly specialized region of the male reproductive tract. \nTo address this knowledge gap\, we used high-resolution tandem mass spectrometry and in-silico analyses to characterize proteome-wide changes in mouse sperm. We studied changes associated with their transit through the epididymis and elicited in response to capacitation stimuli\, such as maturation initiated upon contact with the female reproductive tract. \nIn this webinar\, you’ll learn about: \n\nThe unprecedented depth of >6000 proteins and 14\,586 site-specific phosphorylation events across these sperm populations that we discovered using QIAGEN Ingenuity Pathway Analysis (IPA)\nHow sperm shed over 56% of their proteins during this process\, producing a refined fertilization-competent cell\nHow this reduced proteomic complexity of sperm coincides with the activation of certain functions\, such as sperm motility and capacitation\nKey proteins and kinases we identified through selective pharmacological inhibition that regulate sperm function\nThe role of RHOA on mature spermatozoa to reduce the rate of acrosome reaction by about 40%\n\nOur data represent an essential paradigm shift in our understanding of male fertility regulation. They will contribute to important advancements in developing non-hormonal male contraceptives and robust sperm selection biomarkers for infertile men.
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/the-epididymis-balancing-the-burden-and-responsibility-of-fertility/
LOCATION:Virtual Global Event (Times shown in EST)
CATEGORIES:Discovery,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1233_1_QDI_QDI_IPA_AOP_16x9_63871_Large-1200px.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20231101T150000
DTEND;TZID=UTC:20231101T160000
DTSTAMP:20260403T183354
CREATED:20230912T162020Z
LAST-MODIFIED:20241024T182937Z
UID:10000680-1698850800-1698854400@staging.digitalinsights.supremeclients.com
SUMMARY:RNA-seq Analysis Portal - Analysis of QIAseq miRNA datasets
DESCRIPTION:In this webinar\, we will introduce how to analyze and explore your QIAseq miRNA data in RNA-seq Analysis Portal. \nDuring the webinar\, we will answer the following questions: • Which sample kits are supported by RNA-seq Analysis Portal? • How to upload your data to RNA-seq Analysis Portal? • How to start an analysis? • How to create a project? • How to create an experiment for differential expression? • How to inspect your experiment and quality control of your dataset? • How to view and filter differential expression results? • How to export your results? \nBring any questions you may have and we will answer them during the webinar.
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/rna-seq-analysis-portal-analysis-of-qiaseq-mirna-datasets/
LOCATION:Virtual - EMEA - CET
CATEGORIES:Discovery,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1112_2_Genomics_RAP_Gi899339130.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231101
DTEND;VALUE=DATE:20231106
DTSTAMP:20260403T183354
CREATED:20231030T163815Z
LAST-MODIFIED:20241024T182948Z
UID:10000698-1698796800-1699228799@staging.digitalinsights.supremeclients.com
SUMMARY:ASHG 2023
DESCRIPTION:This year at the American Society for Human Genetics (ASHG) 2023 Annual Meeting\, QIAGEN will be showcasing our Sample to Insight solutions for human genetics at booth #902. Learn more about our products and solutions and receive complimentary demos of our bioinformatic software and databases. Our experts will be available to chat with you and answer any questions you may have. We look forward to seeing you at ASHG 2023.
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/ashg-2023/
LOCATION:Washington\, DC\, United States
CATEGORIES:Clinical,Event
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_5632_GEN_DC_Cherryblossom-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231025T130000
DTEND;TZID=America/New_York:20231025T140000
DTSTAMP:20260403T183354
CREATED:20230927T123320Z
LAST-MODIFIED:20241024T182942Z
UID:10000689-1698238800-1698242400@staging.digitalinsights.supremeclients.com
SUMMARY:Real-World Applications of Clinical Metagenomic Sequencing in Cancer and Infectious Disease Diagnostics
DESCRIPTION:Clinical metagenomic next-generation sequencing (mNGS)\, the comprehensive analysis of microbial and host DNA and RNA in samples from patients\, is rapidly moving from research to clinical laboratories. This emerging approach is changing the diagnosis and treatment of diseases\, with applications in a range of areas\, including oncology\, human host gene expression (transcriptomics)\, and antimicrobial infections and resistance. \nIn this webinar\, Elif Dagdan\, the director of the Center for Medical Genetics at Augusta Hospital Bochum in Bochum\, Germany\, will discuss real-world applications of using clinical mNGS to improve diagnostics of cancer and infectious diseases. The talk will also feature challenges and opportunities of using mNGS in disease diagnostics and how Dagdan’s lab uses clinical variant interpretation and reporting software from Qiagen to detect and characterize pathogenic somatic variants. \nDagdan will discuss: \nHow mNGS can be used to assess homologous recombination deficiency (HRD) status in patients with ovarian cancer.\nHow mNGS can be used to assess cell-free microbial DNA via liquid biopsy to aid in early-stage lung cancer diagnosis.\nHow mNGS can improve the accuracy and speed of infectious disease diagnostics\, with a use-case on cardiovascular infections in intensive care units.
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/real-world-applications-of-clinical-metagenomic-sequencing-in-cancer-and-infectious-disease-diagnostics/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Clinical,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_9002_Genomics_EGS_gi1002000796_16x9_Large-1200px_45500.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231025T110000
DTEND;TZID=America/New_York:20231025T120000
DTSTAMP:20260403T183354
CREATED:20230912T155150Z
LAST-MODIFIED:20241024T182936Z
UID:10000679-1698231600-1698235200@staging.digitalinsights.supremeclients.com
SUMMARY:What's new in QIAGEN IPA Fall Release 2023?
DESCRIPTION:Interested in learning about new features and functionalities that have been added to IPA lately?\nDuring this webinar\, we will highlight the updates from the QIAGEN IPA Fall Release and from previous releases from this year. Topics\, amongst others\, will be\n• Newly added findings and pathways\n• Reactome pathways\n• Artificial intelligence approves to pathways\n• More precise matches in Analysis Match\n• Cell type prediction\n• New queueing view for checking your analysis status\nBring any questions you may have and we will answer them during the webinar.\nIPA release notes are available via the following webpage: https://digitalinsights.qiagen.com/products/qiagen-ipa/latest-improvements/current-line/
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/whats-new-in-qiagen-ipa-fall-release-2023-2/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1269_5_QDI_QDI_IPA_0676.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20231025T093000
DTEND;TZID=Europe/Paris:20231025T103000
DTSTAMP:20260403T183354
CREATED:20230912T154758Z
LAST-MODIFIED:20241024T182936Z
UID:10000678-1698226200-1698229800@staging.digitalinsights.supremeclients.com
SUMMARY:What's new in QIAGEN IPA Fall Release 2023?
DESCRIPTION:Interested in learning about new features and functionalities that have been added to IPA lately?\nDuring this webinar\, we will highlight the updates from the QIAGEN IPA Fall Release and from previous releases from this year. Topics\, amongst others\, will be\n• Newly added findings and pathways\n• Reactome pathways\n• Artificial intelligence approves to pathways\n• More precise matches in Analysis Match\n• Cell type prediction\n• New queueing view for checking your analysis status\nBring any questions you may have and we will answer them during the webinar.\nIPA release notes are available via the following webpage: https://digitalinsights.qiagen.com/products/qiagen-ipa/latest-improvements/current-line/
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/whats-new-in-qiagen-ipa-fall-release-2023/
LOCATION:Virtual - EMEA - CET
CATEGORIES:Discovery,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1269_5_QDI_QDI_IPA_0676.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231024T130000
DTEND;TZID=America/New_York:20231024T143000
DTSTAMP:20260403T183354
CREATED:20230912T154214Z
LAST-MODIFIED:20241024T182936Z
UID:10000677-1698152400-1698157800@staging.digitalinsights.supremeclients.com
SUMMARY:Multi-omics (metabolomics\, proteomics\, transcriptomics) analysis using QIAGEN Ingenuity Pathway Analysis
DESCRIPTION:This 90-minute training session is about how QIAGEN Ingenuity Pathway Analysis (IPA) allows visualization of molecular intricacy and variations at multiple levels such as transcriptome\, proteome\, and metabolome. Through a series of brief technical vignettes\, it is demonstrated how to: \n· Generate associations among molecular signatures obtained via integrating multi-omics data \n· Extract mechanisms from multi-omics data for precision medicine \n· Disease stratification based on multi-omics profiles \n· Map disease networks among targets and indications
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/multi-omics-metabolomics-proteomics-transcriptomics-analysis-using-qiagen-ingenuity-pathway-analysis-2-2/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1036_9_QDI_IPAviral_Gi683847570_16x9_Large-1200px_53562.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20231019T110000
DTEND;TZID=UTC:20231019T120000
DTSTAMP:20260403T183354
CREATED:20230912T164135Z
LAST-MODIFIED:20241024T182938Z
UID:10000684-1697713200-1697716800@staging.digitalinsights.supremeclients.com
SUMMARY:A breakthrough for rare disease: Completing the Clinical exome gap!
DESCRIPTION:In its latest release\, QCI Interpret for Hereditary extends its market-leading content with further advancements in Artificial Intelligence (AI) for enhanced capabilities in clinical exome NGS testing. Now\, with the addition of AI-derived literature references for rare disease genes\, QCI Interpret provides complete exome coverage\, on top of the existing unrivalled manually curated content and bibliography. \nIn this webinar\, we will demonstrate how QCI Interpret is expanding its literature coverage enabling easy and efficient variant filtering workflow\, based on bibliography and on patient’s phenotype. This new feature provides greater control over bibliography context\, allowing users to only look at publications where the causative variant is associated with a specific disease. In addition\, the release provides AI-enhanced phenotype-driven ranking. Using this approach that has been trained using thousands of solved cases\, QCI Interpret for Hereditary Diseases provides superior overall candidate ranking for causative variants in rare diseases. The new variant-ranking approach is enhanced by taking into account additional variant related variables supported also by AI\, as well as the patient’s symptoms\, and all of the manually curated literature in the QIAGEN Knowledge Base to give the best possible chance of reaching an accurate diagnosis. \nLearning objectives: \n\nLearn about QCI Interpret’ s new AI bibliography content providing expanded clinical exome coverage\, due to the combination of the AI-derived literature references with QIAGEN’s unrivalled manual curation.\nLearn about QCI Interpret gives users the best possible chance of reaching an accurate diagnosis by providing phenotype-driven ranking that considers the detected mutations\, the patient’s symptoms\, and all the content in the QIAGEN Knowledge Base.\nView live demonstration of unique features in QCI Interpret\, which can drastically reduce the time spent on solving a case\, resulting in faster turnaround time and an accurate assessment of a case.
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/a-breakthrough-for-rare-disease-completing-the-clinical-exome-gap/
LOCATION:Virtual Global Event (Times shown in EST)
CATEGORIES:Clinical,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1327_7_QDI_QCI_Hereditary_Summit.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231017T130000
DTEND;TZID=America/New_York:20231017T150000
DTSTAMP:20260403T183354
CREATED:20230912T153140Z
LAST-MODIFIED:20241024T182933Z
UID:10000676-1697547600-1697554800@staging.digitalinsights.supremeclients.com
SUMMARY:RNA-seq data analysis and interpretation using QIAGEN CLC and QIAGEN IPA
DESCRIPTION:This 120-minute training will teach you how to easily analyze and interpret RNA-seq data using QIAGEN CLC Genomics Workbench software and QIAGEN Ingenuity Pathway Analysis (IPA). \nFor RNA-seq data\, you will learn how to:\n• Import FASTQ files\, cell matrix files and metadata and how to download references\n• Map reads to a reference genome and generate gene and transcript counts and QC reports displaying % mapped reads\, knee plots\, etc.\n• Generate visualizations of results\, such as heatmaps\, differential expression tables\, PCA/PCOA plots\, Venn diagrams and others\n• Easily customize RNA-seq workflows\n• Export publication-quality graphics\, tables and reports\n• Send differential expression tables to QIAGEN Ingenuity Pathway Analysis directly from QIAGEN CLC Genomics Workbench to analyze and interpret relevant pathways \nExplore the types of analyses and visualizations you’ll learn to generate (slides from previous training): https://qiagen.showpad.com/share/qiZLmCUS32GZNM1B4llMf
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/rna-seq-data-analysis-and-interpretation-using-qiagen-clc-and-qiagen-ipa-2/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Training
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1140_5_QDI_CLC_V22_16x9_Large-1200px_58739.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20231017T090000
DTEND;TZID=Europe/Paris:20231017T100000
DTSTAMP:20260403T183354
CREATED:20231011T152914Z
LAST-MODIFIED:20241024T182942Z
UID:10000690-1697533200-1697536800@staging.digitalinsights.supremeclients.com
SUMMARY:Integrating deeply curated omics data with APIs for biomarkers and drug-target investigation
DESCRIPTION:This webinar is for data scientists and bioinformaticians working in biopharma who need extensive high-quality omics data for target discovery efforts. Learn how to programmatically discover\, retrieve\, filter\, aggregate\, and analyze omics data from QIAGEN’s extensive repositories of deeply-curated multi-omics data. Attendees will learn how to leverage extensive metadata to find and combine datasets of interest\, find and test signatures\, and perform custom analyses to reveal patterns relevant to disease. Join us to learn how QIAGEN OmicSoft Lands API can revolutionize your data analysis workflows and help you make more informed decisions.
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/integrating-deeply-curated-omics-data-with-apis-for-biomarkers-and-drug-target-investigation-2/
LOCATION:Virtual - EMEA - CET
CATEGORIES:Discovery,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1059_9_QDI_OncoLand_028824_Large-1200px_54664.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231012T130000
DTEND;TZID=America/New_York:20231012T143000
DTSTAMP:20260403T183354
CREATED:20230912T144219Z
LAST-MODIFIED:20241024T182932Z
UID:10000675-1697115600-1697121000@staging.digitalinsights.supremeclients.com
SUMMARY:Exploring pan-cancer immunomodulators for biomarker discovery and validation using TCGA and public single-cell data
DESCRIPTION:Cancer outcome is influenced by both the tumor microenvironment and host immune response. Using QIAGEN OmicSoft Studio to access public data from The Cancer Genome Atlas (TCGA) and our human Single Cell Lands collection\, you’ll learn how to:\n• View host immune response clusters across TCGA samples\n• Identify differentially expressed immunomodulators across sample groups\n• Visualize single-cell dimension reduction maps and overlay expression data\n• Identify potential biomarkers whose expression correlates or anti-correlates with target genes\n• Validate new biomarkers using custom queries and TCGA survival data
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/exploring-pan-cancer-immunomodulators-for-biomarker-discovery-and-validation-using-tcga-and-public-single-cell-data/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_9308_BIOX_OmicSoft_Gi576919878_V2_Large-1200px_47746.jpg
END:VEVENT
END:VCALENDAR